Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529684 · ClinicalTrials.gov registry record · Phase 1
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
A Phase 1 study of Advanced Solid Tumors and Pharmacokinetics of 14C-OSI-906, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT01529684 is a Phase 1 study of Advanced Solid Tumors and Pharmacokinetics of 14C-OSI-906 that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 5 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01529684, a Phase 1 study of Advanced Solid Tumors and Pharmacokinetics of 14C-OSI-906, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetics, in particular the routes of excretion and extent of metabolism of OSI-906 after a single oral dose of 14C-labeled OSI-906. Subjects with Advanced Solid Tumors may participate and then continue into the Optional Treatment Phase.
Conditions Studied
Interventions
- DRUG OSI-906
- DRUG radio-labeled OSI-906
Study Locations (2)
Washington
- Northwest Medical Specialties, PLLC - Tacoma
- Comprehensive Clinical Development NW, Inc. - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-03-19 |
| Est. Completion | 2013-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529684
The ClinicalTrials.gov registry entry for NCT01529684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (97% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which OSI-906 is the first listed.
NCT01529684 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01529684 about?
NCT01529684 is a clinical study titled "A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body". The purpose of this study is to evaluate the pharmacokinetics, in particular the routes of excretion and extent of metabolism of OSI-906 after a single oral dose of 14C-labeled OSI-906. Subjects with Advanced Solid Tumors may participate and then continue into the Optional Treatment Phase.
What is the current status of trial NCT01529684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-03-19. Estimated completion is 2013-02-20.
What conditions does trial NCT01529684 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Pharmacokinetics of 14C-OSI-906.
What interventions are being tested in trial NCT01529684?
The interventions under investigation include: OSI-906 (DRUG), radio-labeled OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01529684?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01529684 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.